Found: 7
Select item for more details and to access through your institution.
Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
- Published in:
- Cephalalgia, 2022, v. 42, n. 11/12, p. 1225, doi. 10.1177/03331024221103509
- By:
- Publication type:
- Article
Elevated Production of Docosahexaenoic Acid in Females: Potential Molecular Mechanisms.
- Published in:
- Lipids, 2010, v. 45, n. 3, p. 209, doi. 10.1007/s11745-010-3391-6
- By:
- Publication type:
- Article
Delta-6 desaturase knockout mouse illustrates previously undocumented pathology.
- Published in:
- FASEB Journal, 2007, v. 21, n. 5, p. A701, doi. 10.1096/fasebj.21.5.a701
- By:
- Publication type:
- Article
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 9, p. 1164, doi. 10.1111/head.14390
- By:
- Publication type:
- Article
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 65, doi. 10.1111/head.14234
- By:
- Publication type:
- Article
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01322-7
- By:
- Publication type:
- Article